Advertisement

Selected Proceedings from the First International Congress on ATTR Amyloidosis Conference

Published:November 05, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.09.027
      Transthyretin (ATTR) amyloidosis is a serious illness that can lead to organ failure and eventual death. As ATTR amyloidosis progresses, patients can develop a wide variety of symptoms, including severe neurologic, gastrointestinal, and cardiovascular manifestations. Only in recent years has diagnostic suspicion increased and effective treatments begun to emerge for patients with this debilitating disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect